Prostate Biopsy CPT Changes for 2027: What Urologists Need to Know

2027 CPT update summary Confirmed (CMS final rule, Nov. 4, 2026): the 2027 prostate biopsy family is nine codes: 55705, 55707, 55708, 55709, 55710, 55711, 55714, 55715, and new add-on 55716. Code 55712 is deleted. Reported, verify in the AMA code book: 55706 and 55713 are also deleted, and 55707 to 55711 and 55715 have revised wording. Not a CPT change: CMS finalized a 20% payment reduction for a modifier 25 E/M on the same day as a 0-day global procedure. Payer policies vary separately. |
A urologist performs a transperineal fusion biopsy, the chart says "prostate biopsy," and the charge ticket still points to a code that no longer exists. That is the daily risk when prostate biopsy coding changes. It changed in 2026, when 55700 was deleted, and it shifts again on January 1, 2027.
This guide covers prostate biopsy CPT changes for 2027: what is confirmed, what to verify, and how to prepare documentation and billing workflows. It does not assume a change just because a topic says so, and it separates CPT changes from payer policy.
Why Prostate Biopsy Coding Needs Special Attention in 2027
Prostate biopsies vary widely: transrectal or transperineal access, systematic (regional) or targeted sampling, ultrasound guidance, MRI-ultrasound fusion, or in-bore MRI or CT guidance. The CPT families now describe these differences, so the procedure note has to support the exact code. Not every technical difference creates a separate billable service, and a code is only as defensible as the documentation behind it. Medical necessity, ICD-10-CM linkage, and payer policy still apply, as they did before 2027.
What Has Actually Changed in Prostate Biopsy CPT Coding for 2027?
Coding area | 2026 baseline | 2027 update | Billing impact |
Prostate biopsy codes | 55700 deleted; 55705 revised; 55706 and 55707 to 55715 active | Nine-code family; 55712 deleted; 55716 added; 55706 and 55713 reported deleted | Update charge masters and superbills |
Imaging guidance | Included in 55706 to 55715 descriptors | Imaging remains included in the imaging-guided codes | Check CPT parentheticals before billing separate imaging |
Add-on lesions | +55715 for each additional fusion or in-bore lesion | +55715 now in-bore only; new +55716 for additional fusion-targeted lesions | Match add-on to its primary code |
Documentation | Approach, guidance, sampling | No new rule confirmed, but descriptors are more specific | Notes must show regional and targeted work |
Payer policy | Policies vary | Not a CPT change; review each payer | Avoid avoidable denials |
Verify final descriptors, parentheticals, and effective dates in the AMA CPT 2027 code book.
Prostate Biopsy CPT Codes Urology Practices Should Review
CPT | Service (paraphrased) | 2027 status | Documentation |
55705 | Biopsy, any approach, not imaging-guided | Retained | No imaging guidance used |
55707 | Transrectal, imaging-guided, regional sampling | Retained; wording reported revised | Approach and regional cores |
55708 | Transrectal, regional plus fusion-targeted lesions | Retained; wording reported revised | Regional and targeted work |
55709 | Transperineal, imaging-guided, regional sampling | Retained; wording reported revised | Approach and regional cores |
55710 | Transperineal, regional plus fusion-targeted lesions | Retained; wording reported revised | Regional and targeted work |
55711 | Fusion-targeted lesion(s) only, either approach; first lesion | Revised | Lesions, no regional sampling |
+55716 | Each additional lesion with 55711 | New add-on | Lesion count and sites |
55714 | In-bore CT- or MRI-guided; first targeted lesion | Retained | In-bore guidance used |
+55715 | In-bore; each additional targeted lesion | Retained; revised | Lesion count |
55700, 55712 | Former general code; transperineal fusion-targeted only | Deleted (55700 in 2026; 55712 for 2027) | Do not report |
55706, 55713 | Template saturation; in-bore sextant plus targeted | Reported deleted; verify | Do not report once deleted |
Physician procedure coding is separate from pathology. The pathologist or laboratory bills specimen examination under its own codes.
Transperineal vs. Transrectal Prostate Biopsy: Billing Considerations
Consideration | Transperineal | Transrectal |
Access route | Needle passes through the perineal skin | Needle passes through the rectal wall |
Documentation | Approach, guidance, cores, lesions | Approach, guidance, cores, lesions |
Coding review | 55709, 55710 are approach-specific | 55707, 55708 are approach-specific |
Claim review | Notes must match the approach billed | Notes must match the approach billed |
Under the current families, approach does affect code choice for the regional codes, but 55711, 55716, and the in-bore codes are not approach-specific. Technology alone does not create a separately billable service.
MRI Fusion Prostate Biopsy Coding and Documentation
Fusion biopsies take careful review. Notes should show the MRI-targeted lesions, ultrasound guidance and fusion, targeted versus regional sampling, who performed each part, and what was actually done. Imaging interpretation by a radiologist is a separate service from the biopsy. Check the CPT instructions and NCCI edits before reporting any imaging service with these codes.
☐ Lesion locations and numbers | ☐ Regional sampling done or not |
☐ Guidance method (fusion, in-bore) | ☐ Physician role documented |
☐ Approach (transrectal, transperineal) | ☐ Cores per site recorded |
Common Prostate Biopsy Coding Mistakes That Can Lead to Denials
Common error | Why it is a problem | Billing review |
Incorrect CPT selection | Procedure may not match code | Verify the operative report |
Incomplete documentation | Service details unclear | Review physician notes |
Using deleted codes | Claims reject on old charge masters | Update systems by Jan. 1 |
Imaging guidance reported separately | Possible unbundling | Review CPT and NCCI |
Duplicate reporting | Same service reported twice | Review claim lines |
Payer policy mismatch | Coverage rules not met | Verify payer policies |
Wrong diagnosis linkage | Necessity unsupported | Check ICD-10-CM linkage |
Prostate Biopsy Documentation Checklist for 2027
Tick each item. Completed ÷ 13 = your completion percentage.
☐ Diagnosis and medical necessity | ☐ Procedure indication |
☐ Biopsy approach | ☐ Procedure performed |
☐ Systematic or targeted sampling | ☐ Imaging guidance details |
☐ Physician involvement | ☐ Number and location of samples |
☐ Operative documentation | ☐ Specimen handling and pathology |
☐ CPT and ICD-10-CM selected | ☐ Modifier review |
☐ Payer requirements checked |
|
How 2027 Coding Updates Can Affect Urology Revenue Cycle Management
RCM area | Potential challenge | Recommended improvement |
Coding | Incorrect code assignment | Specialty-specific coding review |
Claims | Missing information | Pre-submission claim checks |
Denials | Repeated coding errors | Root-cause analysis |
A/R | Delayed resolution | Structured follow-up |
Compliance | Outdated coding practices | Regular updates and audits |
Coding errors can cause denials, underpayments, delays, rework, and compliance exposure. We do not predict financial outcomes. CMS's finalized 20% reduction for modifier 25 E/M visits on the same day as a 0-day global procedure may affect payment, so check each code's global period.
Is Your Urology Practice Ready for 2027 CPT Updates?
Question | Yes | No |
1. Has your team reviewed the official 2027 CPT code set? | ☐ | ☐ |
2. Are biopsy procedure notes reviewed before coding? | ☐ | ☐ |
3. Are transperineal and transrectal approaches documented accurately? | ☐ | ☐ |
4. Are MRI fusion workflows reviewed for reporting? | ☐ | ☐ |
5. Is imaging guidance checked against bundling rules? | ☐ | ☐ |
6. Are payer policies reviewed regularly? | ☐ | ☐ |
7. Are coding-related denials tracked and analyzed? | ☐ | ☐ |
Yes answers | What it may mean |
0 to 2 | Significant opportunities to strengthen coding readiness. |
3 to 5 | Some preparation is in place, but further review may help. |
6 to 7 | Strong preparation. Keep monitoring updates and payer rules. |
An educational self-assessment, not a compliance certification.
How Sirius Solutions Global Supports Urology Billing and Revenue Cycle Management
Sirius Solutions Global provides technology-assisted, human-verified medical billing and revenue cycle management for healthcare providers. Services include medical coding, advanced eligibility verification, claims management, denial management, prior authorization, credentialing and re-credentialing, A/R follow-up, medical billing audits, and revenue leakage identification.
For urology practices, a specialty-focused review can surface outdated codes, documentation gaps, claim issues, and workflow inefficiencies as 2027 begins. We do not offer a proprietary prostate biopsy coding product, and no billing partner can guarantee reimbursement.
Frequently Asked Questions
What are the prostate biopsy CPT changes for 2027?
CMS's final rule lists nine codes: 55705, 55707 to 55711, 55714, 55715, and new add-on 55716, with 55712 deleted. Reports say 55706 and 55713 are deleted too. Verify in the code book.
Have prostate biopsy CPT codes changed for 2027?
Yes. The family was restructured in 2026 and refined for 2027, with deletions, revised wording, and one new add-on.
Which CPT codes are used for prostate needle biopsy?
Code 55705 for non-imaging-guided biopsy, and the imaging-guided family such as 55707 to 55711 and 55714, based on approach and guidance.
Is transperineal coded differently from transrectal?
For the regional codes, yes. Transrectal and transperineal each have their own codes, while 55711 and the in-bore codes are not approach-specific.
How is MRI fusion biopsy documented?
Record lesions, guidance method, targeted versus regional sampling, cores, and the physician's role.
What documentation is required?
Medical necessity, indication, approach, guidance, sampling, lesions, samples, and operative notes that support the code.
Can imaging guidance be billed separately?
The imaging-guided codes include guidance in their descriptors. Check CPT parentheticals and NCCI before reporting separate imaging.
Why are prostate biopsy claims denied?
Common reasons are deleted or wrong codes, thin documentation, unbundling, modifier errors, and unmet payer policy.
How can practices prepare for 2027?
Review the AMA code book, update charge masters, retrain staff, audit notes, and check payer policies before January 1.
Why does specialty-specific billing matter?
Urology codes change often, and small descriptor differences affect payment and compliance.
How can a billing company help?
It can support code review, claim scrubbing, denial analysis, and reporting. Sirius offers these services without guaranteeing outcomes.
Sources
CY 2027 MPFS final rule summary (CMS-1848-F), SIR | CMS-1848-F, Federal Register | AUA: 2026 CPT updates | AMA CPT | CMS NCCI
Disclaimer Published by Sirius Solutions Global for educational purposes. This is not legal, coding, or compliance advice. CPT is a trademark of the AMA; descriptors here are paraphrased. Codes marked as reported or unconfirmed must be verified in the official 2027 CPT code book. Payer policies vary. No reimbursement or outcome is guaranteed. Request a correction. |





